Loading clinical trials...
Loading clinical trials...
A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease
Conditions
Interventions
Lucerastat
Locations
42
United States
University of Alabama at Birmingham - Nephrology Research Clinic
Birmingham, Alabama, United States
University of California Irvine
Irvine, California, United States
UCSF Benioff Children's Hospital Oakland
Oakland, California, United States
University of Florida Clinical and Translational Science Institute, UF Clinical Research Center
Gainesville, Florida, United States
Rush University Medical Center - Dept of Pediatrics
Chicago, Illinois, United States
University of Iowa Stead Family Children's Hospital - Division of Medical Genetics
Iowa City, Iowa, United States
Start Date
December 18, 2018
Primary Completion Date
August 1, 2029
Completion Date
November 1, 2029
Last Updated
October 21, 2025
NCT06941025
NCT07382128
NCT05923788
NCT05473637
NCT07277361
NCT04252066
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions